Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT115 mRNA vaccine with neoadjuvant chemotherapy for ovarian cancer
NL-OMON49404Completed
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of BNT115 in ovarian cancer, sponsored by University Medical Center Groningen. Primary endpoint: Systemic induction / expansion of vaccine antigen-specific T cells. Started Dec 2019; status: completed.
02
Drugs
BNT115
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON49404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49404.